MaxCyte vs Rapid Micro Biosystems
Rapid Micro Biosystems reported revenue of $34 million in fiscal 2025, about the same as MaxCyte's $33 million in fiscal 2025. MaxCyte's revenue fell 14.5% in its latest year, and Rapid Micro Biosystems' grew 19.7%. MaxCyte had an operating margin of -157.1%, against -141.1% at Rapid Micro Biosystems. Free cash flow was −$36 million at MaxCyte and −$32 million at Rapid Micro Biosystems.
Side by side
| MaxCyte | Rapid Micro Biosystems | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $33M | $34M |
| Revenue growth | −14.5% | 19.7% |
| Revenue growth a year, last 5 years | 4.7% | 15.9% |
| Gross margin | 81.2% | — |
| Operating margin | −157.1% | −141.1% |
| Net margin | −135.1% | −140.3% |
| Free cash flow | −$36M | −$32M |
| Free cash flow margin | −109.5% | −95.0% |
| Return on capital | — | −192.8% |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 1.5% | 2.5% |
| Last close | $1.28 | $0.74 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $120,780, sold $8,316 | sold $1.1 million |
| Piotroski F-score | — | 2 of 8 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
MaxCyteRapid Micro Biosystems
Operating margin
Percent of revenue
MaxCyteRapid Micro Biosystems
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
MaxCyteRapid Micro Biosystems
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the MaxCyte and Rapid Micro Biosystems pages.